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A B S T R A C T
Background: Due to the lack of nephrotoxic activity, proliferation signal inhibitors (PSI) such as
everolimus are recommended for immunosuppression after heart transplantation, but the assessment
of renal function in patients receiving PSI has led to conﬂicting results. We examined renal integrity and
function using neutrophil gelatinase-associated lipocalin (NGAL) and conventional markers [plasma
creatinine, cystatin C, urine albumin, a1-microglobulin (a1M)] in heart transplant patients, who
underwent conversion to everolimus due to allograft vasculopathy, graft rejection episodes, or renal
function deterioration, and in patients maintained on calcineurin inhibitors (CNI).
Methods: This cross-sectional study included 121 consecutive heart transplant recipients: 44 patients
received CNI-free immunosuppressive therapy with everolimus and 77 patients received CNI. Renal
parameters were determined in plasma and urine samples using standard enzymatic or immunochemi-
cal methods.
Results: Heart transplant recipients receiving everolimus therapy had signiﬁcantly lower NGAL
concentrations in plasma [median (95% CI): 128 (97–176) ng/mL vs. 252 (224–283) ng/mL,
p < 0.001] and urine [median (95% CI): 6.4 (4.5–7.6) ng/g vs. 15.7 (10.2–25.9) ng/g creatinine,
p < 0.001]. In contrast, no signiﬁcant differences were observed between everolimus- and CNI-treated
groups with regard to creatinine and cystatin C, as well as urine albumin and a1M levels. Signiﬁcant
correlations were noted between plasma NGAL and creatinine (r = 0.42, p < 0.001), cystatin C (r = 0.44,
p < 0.001), N-terminal brain natriuretic propeptide (r = 0.31, p < 0.01) and indicators of chronic
inﬂammation [lipoprotein-associated phospholipase A2 (Lp-PLA2), r = 0.31, p < 0.01] and soluble CD40
ligand (sCD40L, r = 0.22, p < 0.05), and between urinary NGAL and a1M (r = 0.21, p < 0.05). Multiple
regression analysis indicated that cystatin C and Lp-PLA2 were the best predictors of plasma NGAL.
Conclusion: The present study documents reduced plasma and urinary NGAL levels in the absence
of differences in conventional renal parameters in patients on CNI-free immunosuppressive therapy
with everolimus. These results support favorable effects of everolimus on renal integrity in heart
transplant recipients.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Cardiac transplantation is now an established treatment for
patients with end-stage heart failure. The introduction of* Corresponding author at: Centrum fu¨r Laboratoriumsmedizin,
Universita¨tsklinikum Mu¨nster, Albert Schweizer Campus 1, Geba¨ude A1,
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightscalcineurin inhibitors (CNI) into immunosuppressive therapy
regimens has signiﬁcantly improved the survival rate among
heart transplant recipients. However, the long-term outcome after
heart transplantation is adversely affected by CNI-induced
nephrotoxicity, which leads to progressive renal deterioration
and ultimately to end-stage renal disease. Proliferation signal
inhibitors (PSI), such as everolimus or sirolimus, exert immuno-
suppressive effects by blocking the growth factor-driven prolifer-
ation of T and B cells [1]. The major advantage of PSI over CNI is reserved.
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nance protocols that partially or fully replace CNI with PSI have
been reported to alleviate renal impairment ([2–4] and references
therein). However, the conversion from CNI to PSI in heart
transplant recipients is not uniformly effective, with a lack of
improvement or even deterioration of kidney function observed
in a few studies [2–4].
The overwhelming majority of previously published reports
have used plasma creatinine concentrations and/or calculated
creatinine clearance for the assessment of renal status after heart
transplantation. Unfortunately, neither variable reliably reﬂects
renal function, the marked deterioration of which can occur prior
to an increase in serum creatinine levels. Neutrophil gelatinase-
associated lipocalin (NGAL), also known as siderocalin, lipocalin-2,
or LCN2, is a 25-kDa glycoprotein with bactericidal properties,
which was initially isolated from activated neutrophils and
subsequently identiﬁed in the epithelial cells of the alimentary
and respiratory tracts, cardiomyocytes, and renal tubular cells
[5,6]. Upregulated NGAL production has been observed in several
inﬂammatory conditions, including inﬂammatory bowel disease,
chronic obstructive pulmonary disease, and myocarditis [5–7]. In
the setting of acute renal failure, serum and urine NGAL levels are
elevated from 7- to 16-fold and from 25- to 100-fold, respectively
[8]. Consequently, NGAL has been suggested as a sensitive
biomarker of acute kidney injury [5,6,8]. However, increased
NGAL concentrations have also been reported in chronic kidney
disease, which presumably reﬂects the protracted damage to
tubular cells irrespective of the glomerular ﬁltration rate (GFR)
[5,9–11]. Therefore, the determination of NGAL levels may aid the
early detection of renal function changes that occur alongside
chronic pathological conditions and can be overlooked using
conventional indicators such as creatinine, cystatin C, or estimated
GFR (eGFR).
Few previous observational studies have reported increased
plasma NGAL concentrations in adult or infant heart transplant
recipients [12–14]. However, the effect of CNI to PSI conversion in
the course of the immunosuppressive therapy after heart
transplantation on plasma or urine NGAL levels has not been
examined to date. This current study reports the novel ﬁndings
of reduced plasma and urine NGAL concentrations in heart
transplant recipients who received a CNI-free immunosuppressive
maintenance regimen that included everolimus.
Materials and methods
Patients, study design, and sample collection
The study was of a cross-sectional design. Ethics board approval
was gained for the study protocol, and written informed consent
was obtained from all patients. The examined cohort included
121 patients after cardiac transplantation recruited at the
Department of Cardiothoracic Surgery, University Hospital Mu¨n-
ster, between January 1990 and December 2010. Excluded patients
included those temporarily treated in other cardiac surgery centers
as well as heart–lung transplants, repeat transplants, pediatric
transplants (<18 years), patients within their ﬁrst year after
transplantation, patients with a history of diabetes that required
insulin, and patients with a diagnosed malignancy. All patients
underwent yearly monitoring for cardiac allograft vasculopathy
(CAV) with dobutamine stress echocardiography and single photon
emission computed tomography. In case of a suspicious result in
either examination, coronary angiography was subsequently
performed. For the present study, patients were examined and
blood and urine samples were taken during 2011 in consecutive
visits to the outpatients department at the Department of
Cardiology. At the time of examination, all patients were freefrom acute rejection, acute heart failure, and clinical signs of
infection. Initially, all patients received the maintenance immu-
nosuppressive therapy, which consisted of CNI [tacrolimus or
cyclosporine A (CsA)], mycophenolate mofetil, and/or a low-dose
steroid (2–5 mg prednisolone daily). The steroid was withdrawn
only if patients developed osteoporosis or diabetes. Beginning in
April 2004, CNI was successively replaced by everolimus in
44 patients. The indications for conversion to everolimus included
CAV (6%), repetitive episodes of graft rejection (6%), and a
deterioration in renal function (88%). Serum creatinine levels
before conversion to everolimus averaged 1.75 (1.50–1.99) mg/dL
and decreased slightly but not signiﬁcantly thereafter. At the time
of the study, patients had been receiving everolimus for at least
6 months. The target trough levels for CsA, tacrolimus, and
everolimus were 120–150 ng/mL, 6–8 ng/mL, and 4–6 ng/mL,
respectively. Statins (with or without ezetimibe) were routinely
given to all patients.
Blood and urine sample collection
Blood samples were collected from patients by venipuncture
during control visits. Samples were centrifuged immediately after
blood collection and plasma or sera were aliquoted and stored at
70 8C until analysis. Overnight urine samples were collected
into vials containing 5.0 mmol/L EDTA to prevent oxidation and
were kept at 70 8C until analysis.
Analytical procedures
Standard clinical chemistry parameters, including serum
creatinine, cystatin C, and C-reactive protein (CRP) and urinary
creatinine were determined at the Center for Laboratory Medicine
using enzymatic, photometric, or immunoturbidimetric assays on
a routine laboratory analyzer (ADVIA 1800, Siemens Healthcare
Diagnostics, Eschborn, Germany). All interassay coefﬁcients of
variation (iCVs) were <6.8%. eGFR was calculated by converting
creatinine (eGFRCrea) or cystatin C (eGFRCyst) values in plasma
using the modiﬁcation of diet in renal disease (MDRD) formula
[15], or the formula described by Hoek et al. [16]. Plasma
concentrations of troponin I (TnI), N-terminal brain natriuretic
propeptide (NT-proBNP), and interleukin-6 (IL-6) were measured
using chemiluminescence immunoassays on laboratory analyzers
(ADVIA Centaur XP or Immulite 2500, both Siemens). All iCVs were
<12%. Urine concentrations of albumin and a1-microglobulin
(a1M) were determined on a BN-II System nephelometer
(Siemens) with iCVs <7.7%. Measurements of NGAL concentrations
in the plasma and urine were performed using a turbidimetric
immunoassay (BioPorto, Gentofte, Denmark) adapted on the
ADVIA 1800 laboratory analyzer. The detection limit of the assay
was 12 ng/mL and the iCVs were 3.6% and 2.5% at low (198 ng/mL)
and high (497 ng/mL) concentrations, respectively. Lipoprotein-
associated phospholipase A2 (Lp-PLA2) activities in the plasma
samples were determined using a colorimetric assay (Cayman
Chemical, Ann Arbor, MI, USA) using 2-thio-platelet activating
factor as a substrate. Lp-PLA2 activity was calculated from the
slope of the kinetic absorption curve and expressed in
mmol  min1  mL1. The iCVs were 5.1% for a low control and
3.8% for a control close to the sample mean. Soluble CD40 ligand
(sCD40L) concentrations in plasma were determined using a
commercially available ELISA kit (IBL, Hamburg, Germany).
Statistical analysis
Exploratory statistics were performed using the MedCalc
Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend,
Belgium). The level of dependence between two categorical
Table 1
Baseline characteristics of the study population.
Everolimus
(n = 44)
CNI (n = 77) p
Age (years) 57  14 56  15 0.75
Female gender 8 (18) 19 (25) 0.54
Body mass index (kg/m2) 25.4  4.6 24.9  4.2 0.51
Diabetes 10 (22) 12 (16) 0.46
Pre-transplant condition
- Ischemic cardiopathy 21 (48) 48 (62) 0.17
- Dilated cardiomyopathy 18 (40) 19 (25) 0.15
- Other 5 (12) 10 (13) 0.95
Time since transplant (years) 8  4 9  6 0.99
Time on everolimus (years) 3.8  1.8 – –
Systolic pressure (mmHg) 121  10 124  9 0.31
Diastolic pressure (mmHg) 77  7 79  8 0.19
Left ventricular ejection
fraction (LEVF, %)
61.5  12.1 62.1  6.9 0.69
Medication
- Everolimus 44 (100) – –
- Tacrolimus – 56 (73) –
- Cyclosporine – 21 (27) –
- Mycophenolate mofetil 32 (72) 60 (80) 0.67
- Azathioprine 1 (2) 5 (6) 0.61
Steroids 43 (98) 67 (87) 0.11
Lipid lowering 43 (98) 74 (96) 0.96
Anti-hypertensive 43 (98) 74 (96) 0.96
Observed trough concentrations
- Everolimus (ng/mL) 5.2  2.1 – –
- Tacrolimus (ng/mL) – 6.9  4.1 –
- Cyclosporin A (ng/mL) – 133.7  71.5 –
According to treatment groups: data are given as mean  SD or rates [relative
rates (%) are shown in parentheses]. CNI (calcineurin inhibitors) include
cyclosporine A or tacrolimus. Medication with steroids includes prednisone or
prednisolone. Medication with lipid-lowering drugs includes simvastatin or
ﬂuvastatin or pravastatin or atorvastatin combined or not with ezetimibe.
Medication with anti-hypertensive drugs includes b-blockers, angiotensin-
converting enzyme inhibitors, sartans, or Ca2+-channel blockers.
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continuous variables was assessed for normality using the Shapiro–
Wilk test. The Student’s t-test (2-sided) or Mann–Whitney U-test (2-
sided) was used to compare groups with normally or non-normally
distributed data, respectively. Spearman’s rank correlation was
calculated to examine correlations between numerical variables.
Stepwise multiple regression analysis was used to determine
independent factors that affected NGAL concentrations in plasma
and urine. Non-normally distributed data were Ln-transformed. The
local signiﬁcance level (p) was set to 0.05. For descriptive purposes,
the relative rates (in percent) were provided for categorical variables
and means (SD) or medians (95% CI) were calculated for normally
or non-normally distributed continuous variables, respectively.
Results
The general characteristics of groups treated with everolimus or
CNI are shown in Table 1. Both groups did not differ signiﬁcantly
with regard to age and sex, as well as body mass index, systolic and
diastolic blood pressure, and left ventricular ejection fraction
(LVEF). Comparable percentages of patients in each group suffered
from type 2 diabetes mellitus. The mean time elapsed from cardiac
transplantation for the entire study population was 8.5  5.6 years
and there was no signiﬁcant difference between both groups.
The everolimus-treated group had received this treatment for
3.8  1.8 years. The indications for transplantation were mainly
coronary heart disease and dilated cardiomyopathy in the ever-
olimus- and CNI-treated groups, respectively. Similar rates of patients
in each group received mycophenolate mofetil and/or low-dose
steroid therapy in addition to everolimus or CNI (CsA or tacrolimus).
The observed trough concentrations of CsA, tacrolimus, and ever-
olimus were within the target ranges. None of the patients examined
was receiving sirolimus therapy or anti-oxidative drug therapy at
the time of the study. No signiﬁcant differences with respect to
lipid-lowering, anti-hypertensive, or anti-coagulant therapy were
present between both groups.
The distributions of variables that reﬂected renal function and
integrity in heart transplant patients receiving immunosuppres-
sive therapy with everolimus or CNI are shown in Table 2. No
signiﬁcant differences between the groups were detected with
regards to plasma creatinine and cystatin C levels, as well as
eGFRCrea and eGFRCyst. Likewise, urinary a1M concentrations and
the urinary albumin/creatinine ratio, which reﬂect tubular and
glomerular kidney injury, respectively, did not signiﬁcantly differ
between the everolimus- and CNI-treated groups. However,
patients who received everolimus presented with signiﬁcantlyTable 2
Renal, cardiac, and inﬂammation markers in the study population.
Everolimus (n = 44) 
NGAL in plasma (ng/mL) 128 (97–176) 
NGAL in urine (ng/mg creatinine) 6.4 (4.5–7.6) 
Creatinine (mg/dL) 1.38 (1.27–1.53) 
eGFRCrea (mL/min/1.73 m
2) 48.4 (43.8–57.5) 
Cystatin C (mg/L) 1.72 (1.40–2.19) 
eGFRCyst (mL/min/1.73 m
2) 43.3 (32.3–53.1) 
Albumin (mg/g creatinine) 69.5 (37.4–112.3) 
a1-Microglobulin (mg/L) 15.6 (11.4–24.3) 
CRP (mg/dL) 0.68 (0.56–0.74) 
IL-6 (ng/mL) 5.01 (3.83–6.55) 
sCD40L (ng/mL) 0.81 (0.44–0.98) 
Lp-PLA2 (mmol/mL/min) 0.008 (0.007–0.009) 
NT-proBNP (mg/mL) 601 (396–1083) 
Troponin I (ng/mL) 0.005 (0.002–0.008) 
Data are given as median (95% CI). CNI (calcineurin inhibitors) include cyclosporine 
NGAL, neutrophil gelatinase-associated lipocalin; eGFR, estimated glomerular ﬁltratio
sCD40L, soluble CD40 ligand; Lp-PLA2, lipoprotein-associated phospholipase A2; NT-lower plasma NGAL concentrations and urinary NGAL/creatinine
ratios compared to the group that received CNI. Conventional
biomarkers of systemic inﬂammation, such as plasma CRP and IL-6
levels, were comparable between both groups examined in this
study. In contrast, heart transplant recipients that received
everolimus showed signiﬁcantly lower levels of plasma Lp-PLA2
activity and sCD40L concentrations. These parameters reﬂect
chronic inﬂammatory processes that are dependent on macro-
phage activation. Biomarkers that reﬂect cardiac integrity and
function (TnI, NT-proBNP) were not signiﬁcantly different between
the everolimus- and the CNI-treated groups.CNI (n = 77) p
252 (224–283) <0.001
15.7 (10.2–25.9) <0.001
1.48 (1.28–1.71) 0.36
55.5 (44.5–59.6) 0.52
1.72 (1.48–2.02) 0.90
43.4 (35.4–50.0) 0.63
56.9 (29.3–64.9) 0.65
17.7 (12.9–24.9) 0.51
0.64 (0.57–0.82) 0.34
4.06 (3.35–4.90) 0.13
1.21 (0.82–1.67) <0.05
0.010 (0.009–0.011) <0.001
737 (507–972) 0.79
0.006 (0.004–0.010) 0.35
A or tacrolimus.
n rate; Crea, creatinine; Cyst, cystatin C; CRP, C-reactive protein; IL, interleukin;
proBNP, N-terminal brain natriuretic propeptide.
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function and integrity markers, correlations between parameters
that reﬂected renal function, systemic and local inﬂammation,
as well as cardiac biomarkers were examined. As shown in Fig. 1,
plasma NGAL concentrations signiﬁcantly correlated with plasma
levels of creatinine, cystatin C, eGFRCrea, eGFRCyst, sCD40L, and
NT-proBNP, as well as Lp-PLA2 activity. In contrast, the urinary
NGAL/creatinine ratio correlated solely with the urinary a1M
concentration. Parameters that tended to correlate with NGAL
(p < 0.10) were subsequently included in the stepwise multiple
regression analysis. For circulating levels of NGAL, the best
predictor was plasma cystatin C (b = 0.32, p < 0.01), which
accounted for 11% of the plasma NGAL concentration. This was
followed by Lp-PLA2 (b = 0.28, p < 0.01), which explained 8% of
the plasma NGAL concentration. Similar results were obtained
when eGFRCyst was substituted for plasma cystatin C. No
predictors of urinary NGAL could be identiﬁed in the multiple
regression analysis.-1.0
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Fig. 1. Correlations between neutrophil gelatinase-associated lipocalin (NGAL)
concentrations in serum and urine and renal, cardiac, and inﬂammatory markers in
everolimus- and calcineurin-inhibitor (CNI)-treated heart transplant recipients.
Correlations between variables were examined using the Spearman rank
correlation test. Non-parametric data are presented after Ln-transformation.
Solid lines: correlation; dotted lines: conﬁdence intervals. (A) Creatinine; (B)
estimated glomerular ﬁltration rate for creatinine (eGFRCrea); (C) cystatin C; (D)
estimated glomerular ﬁltration rate for cystatin C (eGFRCyst); (E) lipoprotein-
associated phospholipase A2 (Lp-PLA2); (F) soluble CD40 ligand (sCD40L); (G) N-
terminal brain natriuretic propeptide (NT-proBNP); and (H) a1-microglobulin.Discussion
As a result of the lack of intrinsic nephrotoxic activity, the use of
PSI such as everolimus has been frequently recommended for
immunosuppressive therapy after heart transplantation. However,
the results of clinical studies that compared PSI with CNI in heart
transplant recipients have been supportive, neutral, or even
negative with regard to adverse effects on renal function after
patients were switched to PSI-based regimens [2–4]. Prompted by
the ongoing controversy regarding the conversion of CNI to PSI in
heart transplant maintenance therapy, we assessed renal integrity
and functional status in heart transplant patients who underwent
conversion to everolimus or were maintained on CNI therapy. We
assessed levels of NGAL, a sensitive indicator of early tubular
injury, as well as conventional renal biomarkers (urine albumin,
a1M, plasma creatinine, cystatin C, eGFRCrea, and eGFRCyst). The
novel ﬁnding was observed of lower NGAL concentrations in both
the urine and plasma of patients receiving CNI-free therapy with
everolimus. Importantly, reduced NGAL levels in everolimus-
treated heart transplant recipients were determined in the absence
of signiﬁcant differences between both groups with respect to
plasma creatinine, cystatin C, and eGFR, as well as urinary
concentrations of albumin and a1M. These results could be
interpreted as an indication of the beneﬁcial effects exerted by
everolimus, which were not adequately reﬂected by changes in
conventional markers of renal integrity and function.
NGAL expression is markedly upregulated within the thick
ascending limb of Henle and the collecting duct during ischemic or
toxic renal injury, and the resulting release of NGAL into the urine
accounts for the major fraction of urinary NGAL [5,6,9,17]. Accord-
ingly, increased NGAL excretion into the urine has been observed
in a variety of renal diseases (e.g. polycystic kidney disease,
immunoglobulin A nephropathy, human immunodeﬁciency virus
nephropathy), in which it closely reﬂects the magnitude of renal
tubular injury [18–20]. In the setting of chronic heart failure (CHF),
elevated levels of urinary NGAL paralleled by the increased
excretion of kidney injury molecule-1 and N-acetyl-b-D-glucosa-
minidase, sensitive and speciﬁc markers of tubular damage, have
been observed in several studies [21–24]. Importantly, increased
NGAL excretion could be used to predict unfavorable outcomes,
even in patients with normal renal function as assessed by plasma
creatinine levels, eGFR, and the concentration of urinary albumin
[23]. These ﬁndings were corroborated by the results of the
present study, which failed to observe correlations between the
conventional indices of renal function and NGAL concentrations in
urine and to identify predictors of urinary NGAL in the multiple
regression analysis. Given the capability of urinary NGAL to
speciﬁcally predict kidney injury and the close relationship
between NGAL excretion and the extent of tubular damage, it is
reasonable to assume that patients that received CNI-free therapy
with everolimus have a lower risk of developing renal impairment.
In a major contrast to NGAL excretion in urine plasma, NGAL
levels were found to be closely related to indicators of renal
function (serum creatinine, cystatin C levels, eGFRCrea, and
eGFRCyst), as well as markers of heart function (NT-proBNP) and
chronic inﬂammation (Lp-PLA2 and sCD40L). The distinct origins of
excreted and circulating NGAL may account for these differing
ﬁndings. Whereas NGAL concentrations in the urine are directly
determined by tubular damage, the direct contribution of kidney
injury to circulating NGAL has been questioned; indeed, other
tissues and cells may represent its main source in plasma
[5,6,25]. For example, NGAL expression in cardiomyocytes is
upregulated by several fold in the failing myocardium in response
to hypoxia or pro-inﬂammatory factors [26]. Accordingly, correla-
tions between plasma NGAL levels and CHF severity, as reﬂected by
New York Heart Association class, LVEF, and NT-proBNP levels,
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lated by the ﬁndings of the present study [26–29]. In addition,
activated inﬂammatory cells, such as neutrophils and macro-
phages, may represent an important source of circulating NGAL.
The close relationship between NGAL concentrations in plasma
(but not urine) and indicators of systemic inﬂammation, such as
tumor necrosis factor a, have been described in diverse clinical
settings that include CHF and ischemic cerebrovascular disease
[26,29,30]. The present investigation extends these ﬁndings by
showing the novel association between plasma NGAL levels and
markers of chronic inﬂammatory processes, such as Lp-PLA2 and
sCD40L. Both Lp-PLA2 and sCD40L are independent risk predictors
of coronary ischemic disease, in which they are believed to reﬂect
the magnitude of macrophage activation in atherosclerotic lesions.
In this context, it is worth observing that increased plasma NGAL
levels have been reported in coronary ischemic disease and that
NGAL can be detected within atherosclerotic plaques [31,32]. The
close relationship between sCD40L, Lp-PLA2, and NGAL levels
revealed in the present study may indicate common upstream
mechanisms, which locally regulate these factors during the
pathogenesis of atherosclerotic vasculopathy and which may be
somewhat distinct from mechanisms that govern the expression
of systemic inﬂammation markers, such as IL-6 and CRP.
No deﬁnitive conclusion can be drawn from the present study
as to which mechanisms might account for the lower levels of
urinary and plasma NGAL observed in heart transplant recipients
after conversion to everolimus. Although it is conceivable that the
discontinuation of nephrotoxic CNI therapy directly limits the
extent of tubular damage, the contribution of other, indirect
mechanisms cannot be dismissed. The development of renal
impairment as a consequence of diverse pathological processes in
the myocardium and coronary vasculature culminating in cardiac
dysfunction, a condition known as cardiorenal syndrome, has been
described in CHF, in which it is accompanied by elevated plasma
NGAL levels [33,34]. Everolimus has been previously demonstrated
to prevent endomyocardial remodeling and reduce development of
vascular lesions in both heart transplant recipients and in animal
models of CAV and atherosclerosis [35–39]. In addition, this
compound was found to inhibit the inﬁltration of macrophages
into vascular wall and the release of pro-inﬂammatory factors,
such as chemokines and Lp-PLA2 [39,40]. Based on these ﬁndings
and the results of the present study, it is tempting to hypothesize
that everolimus helps to sustain renal integrity indirectly via
limiting inﬂammatory processes in the heart and thereby counter-
acting the development of cardiac dysfunction and cardiorenal
syndrome.
Several limitations of the present study have to be acknowl-
edged. Firstly, as the patient recruitment was conﬁned to a
single transplantation center, only a moderate number of heart
transplant recipients could be included in the study. The power of
the study is therefore limited and a thorough statistical analysis
of confounding factors is precluded. Secondly, the study was
performed in a cross-sectional design and, with the exception of
creatinine, no information was available regarding parameters
of renal function prior to the initiation of everolimus therapy.
Accordingly, the present ﬁndings do not constitute unequivocal
evidence that established NGAL as an early indicator of renal
deterioration during CNI-based immunosuppression. Neverthe-
less, the present ﬁndings clearly demonstrate reduced plasma and
urinary NGAL levels in everolimus-treated patients irrespective of
the time elapsed from their conversion to CNI-free therapy.
Consequently, they mandate the establishment of further pro-
spective observational studies that will aim to appraise the utility
of NGAL as a marker of early kidney injury in patients who receive
post-transplant immunosuppressive therapy. Additional research
will also be necessary to fully elucidate the direct and/or indirectmechanisms that underlie the beneﬁcial renal effects of ever-
olimus in patients after heart transplantation.
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